Extended susceptibility testing for refractory Helicobacter pylori infection: regional testing should guide antimicrobial decision making
Maria Paroikaki, Harin Navalan, Scott J. C. Pallett, Nabeela Mughal, Frances Davies, Saleh A. Alqahtani, Luke S. P. Moore · 2025
Read Extended susceptibility testing for refractory Helicobacter pylori infection: regional testing should guide antimicrobial decision making by Maria Paroikaki, Harin Navalan, Scott J. C. Pallett, Nabeela Mughal, Frances Davies, Saleh A. Alqahtani, Luke S. P. Moore (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12821947.txt.
Description
Maria Paroikaki and co-authors report drug resistance patterns for hard to treat Helicobacter pylori infections in a 2025 study. The bacterium is a common cause of stomach inflammation, and standard two drug cures can fail. Fresh local data for the United Kingdom after the pandemic were lacking.
The team reviewed biopsy samples sent to a London laboratory between 2018 and 2023, covering 193 isolates. Resistance was low for two drugs, moderate for two others, and very high for one common agent. The authors compare the pattern with European registry data. They argue that regional testing should guide drug choice when first cures fail, rather than relying on habit or distant data.
Catalog record
| CREATOR | Maria Paroikaki, Harin Navalan, Scott J. C. Pallett, Nabeela Mughal, Frances Davies, Saleh A. Alqahtani, Luke S. P. Moore |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 18 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |